Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have been given a consensus recommendation of “Buy” by the twenty-four brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, twenty have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $212.6667.

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company reduced their target price on shares of Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, March 23rd. TD Cowen set a $241.00 target price on shares of Insmed in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Cantor Fitzgerald upped their price target on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, HC Wainwright upped their price target on Insmed from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Thursday, March 26th.

Insider Activity

In related news, COO Roger Adsett sold 88,060 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued at $7,831,483.58. This represents a 27.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 198,992 shares of company stock valued at $31,660,112 over the last 90 days. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insmed

Several large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC lifted its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. Kingsview Wealth Management LLC lifted its stake in Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the period. Choreo LLC lifted its stake in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 65 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Insmed by 10.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 69 shares during the period. Finally, ORG Partners LLC lifted its stake in Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 74 shares during the period.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Wall Street coverage remains constructive overall (multiple Buy/Outperform ratings and high consensus targets), which could limit downside if the company demonstrates growth from its core pulmonary franchise and other programs.
• Positive Sentiment: Large institutional holders (e.g., Norges Bank, Vanguard, RTW, Artisan) hold meaningful stakes and reported recent additions, providing a base of long-term ownership that can stabilize the stock after headline-driven moves. Read More.
• Neutral Sentiment: CEO William Lewis sold 10,699 shares (~$1.75M) under a pre-arranged Rule 10b5-1 plan; the sale reduces optics of an unexpected insider exit but is planned and routine. Read More.
• Neutral Sentiment: Billionaire investor Stan Druckenmiller has trimmed a position in INSM (media-reported portfolio activity); depending on size/timing this is a data point but not necessarily a fresh conviction shift. Read More.
• Neutral Sentiment: The company said the Phase 2b CEDAR study showed no new safety signals for brensocatib, which reduces regulatory/safety surprise risk even though efficacy failed. Read More.
• Negative Sentiment: Insmed will discontinue the brensocatib (Brinsupri) HS program after the Phase 2b CEDAR trial missed primary and secondary endpoints (placebo outperformed treatment). Loss of this indication reduces pipeline optionality and expected future revenue, pressuring valuation. Read More.
• Negative Sentiment: Market reaction included a trading halt on the day of the announcement and immediate share weakness as multiple outlets reported the flop — signals of near-term volatility and investor disappointment. Read More.

Insmed Price Performance

Insmed stock opened at $160.18 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market cap of $34.57 billion, a P/E ratio of -24.99 and a beta of 1.10. The business’s fifty day moving average is $150.48 and its two-hundred day moving average is $167.03. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the company posted ($1.32) earnings per share. Insmed’s revenue for the quarter was up 152.6% on a year-over-year basis. Equities research analysts forecast that Insmed will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.